CUG-BP2 Antibody (1H2): sc-47731

CUG-BP2 Antibody (1H2) is a mouse monoclonal IgG1 kappa light chain antibody that detects CUG-BP2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-CUG-BP2 antibody (1H2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CUG-BP2 plays a crucial role in RNA metabolism regulation, particularly in myotonic dystrophy, a neuromuscular disorder characterized by a (CTG)n repeat expansion in the 3′-untranslated region of the myotonin protein kinase gene (DMPK). CUG-BP2 is primarily located in the nucleus, where CUG-BP2 binds to (CUG)8 oligonucleotides, and nuclear localization is essential for modulating the splicing and translation of target RNAs. In normal cells, CUG-BP2′s activity remains tightly regulated, but in myotonic dystrophy cells, binding activity increases significantly, leading to dysregulation of gene expression. CUG-BP2′s interaction with other RNA-binding proteins, such as CUG-BP1, further highlights CUG-BP2′s importance in the cellular response to RNA repeat expansions, making CUG-BP2 a critical target for understanding molecular mechanisms underlying myotonic dystrophy and potentially other related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CUG-BP2 Antibody (1H2) References:

1. CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms.  |  Timchenko, NA., et al. 1999. Nucleic Acids Res. 27: 4517-25. PMID: 10536163
2. The CUG-binding protein binds specifically to UG dinucleotide repeats in a yeast three-hybrid system.  |  Takahashi, N., et al. 2000. Biochem Biophys Res Commun. 277: 518-23. PMID: 11032753
3. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.  |  Timchenko, NA., et al. 2001. J Biol Chem. 276: 7820-6. PMID: 11124939
4. Molecular basis for impaired muscle differentiation in myotonic dystrophy.  |  Timchenko, NA., et al. 2001. Mol Cell Biol. 21: 6927-38. PMID: 11564876
5. Isolation and expression of Napor/CUG-BP2 in embryo development.  |  Choi, DK., et al. 2003. Biochem Biophys Res Commun. 305: 448-54. PMID: 12763013
6. Dynamic antagonism between RNA-binding protein CUGBP2 and cyclooxygenase-2-mediated prostaglandin E2 in radiation damage.  |  Murmu, N., et al. 2004. Proc Natl Acad Sci U S A. 101: 13873-8. PMID: 15358864
7. CUGBP2 downregulation by prostaglandin E2 protects colon cancer cells from radiation-induced mitotic catastrophe.  |  Natarajan, G., et al. 2008. Am J Physiol Gastrointest Liver Physiol. 294: G1235-44. PMID: 18325984
8. CUGBP2 directly interacts with U2 17S snRNP components and promotes U2 snRNA binding to cardiac troponin T pre-mRNA.  |  Goo, YH. and Cooper, TA. 2009. Nucleic Acids Res. 37: 4275-86. PMID: 19443441
9. The CUGBP2 splicing factor regulates an ensemble of branchpoints from perimeter binding sites with implications for autoregulation.  |  Dembowski, JA. and Grabowski, PJ. 2009. PLoS Genet. 5: e1000595. PMID: 19680430
10. Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy.  |  Jakstaite, A., et al. 2016. Langenbecks Arch Surg. 401: 99-111. PMID: 26691217
11. RNA binding protein CUGBP2/ETR-3 regulates STAT3 alternative splicing.  |  Kise, M., et al. 2024. Biochem Biophys Res Commun. 739: 151000. PMID: 39550869
12. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy.  |  Timchenko, LT., et al. 1996. Nucleic Acids Res. 24: 4407-14. PMID: 8948631

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CUG-BP2 Antibody (1H2) has 9 citations in a variety of scientific publications.

Primary antibodies like Anti-CUG-BP2 Antibody (1H2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CUG-BP2 Antibody (1H2) Specifications

Alternate Product Name: CUG-BP2

Product Clone Name: 1H2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 209-415

Epitope Target: CUG-BP2

Epitope Species: human

Product Reactivity/Detection: CUG-BP2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for CUG-BP2 Antibody (1H2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred CUG-BP1/2 antibody is CUG-BP1/2 Antibody (B-1): sc-166095.